$3.04
6.61%
Nasdaq, Sep 02, 10:00 pm CET
ISIN
US9840152063
Symbol
XBIO

Xenetic Biosciences, Inc. Stock price

$3.04
-0.16 5.05% 1M
-1.02 25.16% 6M
-0.95 23.85% YTD
-1.05 25.71% 1Y
-4.36 58.94% 3Y
-5.96 66.24% 5Y
-1,739.36 99.83% 10Y
-590.96 99.49% 20Y
Nasdaq, Closing price Tue, Sep 02 2025
+0.19 6.61%
ISIN
US9840152063
Symbol
XBIO
Industry

Key metrics

Basic
Market capitalization
$4.4m
Enterprise Value
$-380.0k
Net debt
positive
Cash
$4.8m
Shares outstanding
1.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.8 | 1.7
EV/Sales
negative | negative
EV/FCF
0.2
P/B
1.0
Financial Health
Equity Ratio
87.0%
Return on Equity
-65.9%
ROCE
-73.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$2.5m | $2.6m
EBITDA
- | $-4.4m
EBIT
$-3.3m | $-4.4m
Net Income
$-3.1m | $-3.2m
Free Cash Flow
$-2.5m
Growth (TTM | estimate)
Revenue
-2.8% | 2.0%
EBITDA
- | -
EBIT
34.8% | -25.3%
Net Income
34.5% | 19.2%
Free Cash Flow
26.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -172.0%
EBIT
-133.5%
Net
-126.0% | -125.7%
Free Cash Flow
-103.0%
More
EPS
$-2.0
FCF per Share
$-1.6
Short interest
1.5%
Employees
2
Rev per Employee
$1.3m
Show more

Is Xenetic Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Xenetic Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Xenetic Biosciences, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Xenetic Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2.45 2.45
3% 3%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.77 2.77
24% 24%
113%
- Research and Development Expense 2.95 2.95
24% 24%
120%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -3.27 -3.27
35% 35%
-133%
Net Profit -3.08 -3.08
34% 34%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about Xenetic Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xenetic Biosciences, Inc. Stock News

Neutral
Accesswire
21 days ago
Expanded strategic partnership with The Scripps Research Institute to advance proof-of-concept studies and further develop its program combining systemic DNase I with CAR T-cell therapies Ended the quarter with $4.8 million of cash to fund operations FRAMINGHAM, MA / ACCESS Newswire / August 13, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical com...
Neutral
Accesswire
about one month ago
Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its ...
Neutral
Accesswire
about one month ago
Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncolog...
More Xenetic Biosciences, Inc. News

Company Profile

Xenetic Biosciences, Inc. engages in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient's malignant tumor cells. Its product pipeline includes XCart Platform and Polyxen. The company was founded on August 9, 2011 and is headquartered in Framingham, MA.

Head office United States
CEO James Parslow
Employees 2
Founded 2011
Website www.xeneticbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today